GPs judging the RBR to be unfavourableb | GPs reporting that stopping is requiredc | GPs choosing not to stop the drug while judging its RBR to be unfavourable | |
---|---|---|---|
Treatment | n/N (%) | n/N (%) | n/N (%) |
Lorazepam | 929/1025 (90.6) | 934/1032 (90.5) | 70/1183 (5.9) |
Paracetamol and tramadol | 697/1016 (68.6) | 562/1011 (55.6) | 176/1183 (14.9) |
Amitriptyline | 785/1010 (77.7) | 673/1006 (66.9) | 147/1183 (12.4) |
Rosuvastatind | 135/477 (28.4) | 124/487 (25.4) | 38/1183 (3.2) |
↵a Weighted data.
↵b Among the GPs reporting that some prescription drugs presented more risks than benefits (88.6% of all responding GPs).
↵c Among the GPs reporting that some prescription drugs should be stopped (90.0% of all responding GPs).
↵d Among the GPs questioned about a version of the clinical vignette, including a history of stroke. RBR = risk–benefit ratio.